文献速递淋巴瘤

双侧放疗后继以甲氨蝶呤为基础化疗治疗原发性玻璃体视网膜淋巴瘤

Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.
PubMed 文献 · Am J Hematol · 2019-02-04

该研究报告12例原发性玻璃体视网膜淋巴瘤患者,其中10例接受双侧放疗(30-40 Gy)后继以含大剂量甲氨蝶呤的系统化疗,1例仅放疗,1例玻璃体内甲氨蝶呤注射,全部达完全缓解;中位随访68个月,中位无进展生存和总生存均未达到,双侧放疗后甲氨蝶呤为基础化疗可有效减少中枢神经系统进展并延长生存。

要点

  • 10例接受双侧放疗(30-40 Gy)后含大剂量甲氨蝶呤化疗,1例仅放疗,1例玻璃体内甲氨蝶呤,全部达完全缓解。
  • 3例出现脑部肿瘤复发并接受化疗,1例眼部复发后二次脑部复发。
  • 中位随访68个月(范围17-154个月),中位无进展生存和总生存均未达到。

核心结论

  • 双侧放疗后继以甲氨蝶呤为基础化疗是减少中枢神经系统进展并延长生存的有效治疗。

研究设计与样本

  • 报告12例原发性玻璃体视网膜淋巴瘤患者接受双侧放疗联合含大剂量甲氨蝶呤系统化疗的治疗结果。

主要发现

  • 10例接受放疗(30-40 Gy)后化疗,1例接受放疗,1例接受玻璃体内甲氨蝶呤注射,全部达完全缓解。
  • 3例脑部肿瘤复发并接受化疗,1例眼部复发并二次脑部复发。
  • 3例达第二次完全缓解且存活,1例死于痴呆,1例死于复发性中枢神经系统疾病。
  • 中位随访68个月(范围17-154个月),中位无进展生存和总生存均未达到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary vitreoretinal lymphoma (PVRL) is a subset of primary CNS lymphoma that presents as isolated ocular disease without brain involvement. Although ocular radiotherapy (RT) is an effective treatment for PVRL, the optimal treatment is uncertain. PVRL may later involve the brain in 56%-85% of patients. We report on 12 PVRL patients treated with a combination of bilateral RT and a systemic chemotherapy (CT) regimen containing high-dose methotrexate (M). Ten received RT (30-40 Gy) followed by CT, one received RT, and one was treated with intravitreal M; all achieved a complete response (CR). Three patients had tumor recurrence in the brain and received CT and one patient relapsed in the eye with a second recurrence in the brain. Three patients achieved CR-2 remain alive and one died of dementia. One died from recurrent CNS disease. With a median follow of 68 months (range, 17-154 months), median progression-free and overall survival have not been reached. Bilateral RT followed by M-based CT is an effective treatment for reducing CNS progression and prolonging survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. de la Fuente MI, Alderuccio JP, Reis IM, et al. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. Am J Hematol. 2019. PMID: 30663807. doi:10.1002/ajh.25414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。